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Background: Venous thromboembolism (VTE) is a potentially preventable cause of death in people with lung cancer.
Identification of those most at risk and high-risk periods may provide the opportunity for better targeted intervention.
Methods: We conducted a cohort study using the Clinical Practice Research Datalink linked to Hospital Episode Statistics and
Cancer Registry data. Our cohort comprises 10 598 people with lung cancer diagnosed between 1997 and 2006 with follow-up
continuing to the end of 2010. Cox regression analysis was performed to determine which demographic, tumour and treatment-
related factors (time-varying effects of chemotherapy and surgery) independently affected VTE risk. We also determined the effect
of a VTE diagnosis on the survival of people with lung cancer.
Results: People with lung cancer had an overall VTE incidence of 39.2 per 1000 person-years (95% confidence interval (CI),
35.4–43.5), though rates varied depending on the patient group and treatment course. Independent factors associated with
increased VTE risk were metastatic disease (hazard ratio (HR)¼ 1.9, CI 1.2–3.0 vs local disease); adenocarcinoma subtype (HR¼ 2.0,
CI 1.5–2.7, vs squamous cell; chemotherapy administration (HR¼ 2.1, CI 1.4–3.0 vs outside chemotherapy courses); and diagnosis
via emergency hospital admission (HR¼ 1.7, CI 1.2–2.3 vs other routes to diagnosis). Patients with VTE had an approximately 50%
higher risk of mortality than those without VTE.
Conclusions: People with lung cancer have especially high risk of VTE if they have advanced disease, adenocarcinoma or are
undergoing chemotherapy. The presence of VTE is an independent risk factor for death.
Lung cancer accounts for 20% of all cancer-related venous
thromboembolism (VTE) (Levitan et al, 1999; Blom et al, 2006;
Walker et al, 2012), and is associated with a higher incidence of
VTE than the average for all cancer patients (Horsted et al, 2012).
Venous thromboembolism can adversely affect survival in lung
cancer patients (Blom et al, 2004; Huang et al, 2012). Since only a
small fraction of lung cancer deaths might be attributable directly
to VTE events (Dentali et al, 2008), it is possible that the
occurrence of VTE often reflects the underlying aggressiveness of
the cancer. However, VTE still may cause additional morbidity and
disrupt treatment (Kuderer et al, 2009).
Clinical trials demonstrate that VTE can be substantially
reduced by administration of prophylactic low molecular weight
heparin (LMWH) (Verso et al, 2010; Agnelli et al, 2012), but this
may not lead to improvement of survival, as observed in the
FRAGMATIC trial (Griffiths et al, 2009; Noble, 2014) It may be
that thromboprophylaxis needs to be better targeted to confer a
survival benefit. Current guidelines (Streiff et al, 2011; Kahn et al,
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2012; Lyman et al, 2013) indicate that some cancer patients would
benefit from this intervention, including those receiving day case
delivered chemotherapy. In addition, it is important for physicians
to know which patients are at risk of VTE, so that patients
developing VTE can be diagnosed and treated quickly.
Previous studies have identified various high-risk groups for
VTE in lung cancer patients, including those with late-stage cancer
(Tagalakis et al, 2007; Chew et al, 2008; Kadlec et al, 2014),
adenocarcinoma (Blom et al, 2004; Tagalakis et al, 2007; Chew
et al, 2008; Kadlec et al, 2014), surgery (Connolly et al, 2012),
chemotherapy (Blom et al, 2004; Numico et al, 2005; Connolly
et al, 2012; Kadlec et al, 2014) and high platelet count (Zecchina
et al, 2007). However, none of these studies have been detailed
enough to assess their relative importance and ensure their effects
are independent. Recent linkage of four UK healthcare databases
enables us to study the majority of suspected risk factors for
VTE in lung cancer patients. This study uses these databases to
determine the precise rates of VTE in lung cancer patients
according to tumour type and stage, treatment and other potential
risk factors, including age, body mass index (BMI) and pre-existing
comorbidity.
MATERIALS AND METHODS
Patients and data sources. Our cohort comprises data from four
linked healthcare sources: The Clinical Practice Research Datalink
(CPRD), Hospital Episodes Statistics (HES), the National Cancer
Data Repository (NCDR) and Office for National Statistics (ONS)
death certificate data. The present analysis uses patients from
approximately 50% of CPRD practices in England, for whom
linked data are available.
We selected all patients who had a first lung cancer diagnosis
(ICD-10 code C50) between 1 April 1997 and 31 December 2006
(the period from which cancer registry data linked to the CPRD
were available). Patients were followed up until they developed a
VTE event, died, left a participating GP practice or 31 December
2010, whichever was earliest. Date of cancer diagnosis was the
earliest recorded cancer registry date. Patients were excluded for
the following reasons:
 If they were under 18 years.
 If they were not in a linked general practice.
 If they were diagnosed with lung cancer outside the CPRD and
HES registration period.
 If they were diagnosed in the first year of registration at a
participating practice.
 If they had a VTE before first cancer diagnosis.
Exposures. Cancer stage, pathological type and grade were
obtained from cancer registry data. Where known, we classified
stage as ‘local disease’ (confined to the lung), ‘regional disease’ (any
lymph-node involvement) or ‘distant metastases’. Route of
diagnosis was taken from the admission method of the closest
hospitalisation event to the cancer diagnosis date, assuming it
occurred within 1 month of diagnosis. Cancer treatments were
defined by an OPCS-4 code in the HES data, with additional
treatment data obtained from cancer registry data. Surgery codes
were specific to procedures used in the treatment of lung cancer.
To ascertain radiotherapy treatments, we used cancer registry data
exclusively, as radiotherapy is under recorded in HES data (NCIN,
2012). Chemotherapy events recorded within 28 days of each other
were grouped together to determine the treatment periods. Patients
recorded as having chemotherapy in the cancer registry data, but
without a corresponding in-patient record, were assumed to have
had outpatient chemotherapy and were included in a separate
group, as their timing of treatment could not be determined.
Smoking status and BMI were determined from GP records using
the latest recording before cancer diagnosis. GP records were also
used to calculate Charlson comorbidity score (Charlson et al, 1987)
(grouped as 0, 1–3 and 4þ , with cancer excluded). Platelet
count was determined from GP test records, with repeated tests
incorporated in a time-varying manner.
Outcome. A VTE event was confirmed when a relevant
medical code in either the CPRD and HES was supported by an
anticoagulant prescription or medical code providing evidence of
anticoagulation, between 15 days before and 90 days after the VTE
event date, or if death occurred within 30 days of the event.
Additionally, an underlying cause of death of VTE was included as
evidence of a valid VTE event. Only the first VTE event following
the cancer diagnosis was considered. This algorithm for defining
VTE has been previously validated (Lawrenson et al, 2000).
Statistical methods. Person-time commenced at the time of lung
cancer diagnosis, unless a patient had surgery in the 90 days
preceding diagnosis, where follow-up started from surgery date.
Person-time ended when an outcome (VTE or death) was
experienced, or when patients left a contributing general practice.
Absolute rates of VTE (uniformly expressed per 1000 person-
years) were calculated for all patients and then separately for
exposure categories. A Cox proportional hazards model was
created to incorporate all the measured exposures. BMI, comor-
bidity, pathological type, route of diagnosis, cancer stage, cancer
grade and radiotherapy treatment were all time-independent
(fixed-time) covariates, while other cancer treatments (surgery
and chemotherapy) and platelet count were allowed to vary over
time. For surgery and chemotherapy, we measured VTE risk (i)
before treatment, (ii) during treatment (chemotherapy) and (iii) in
monthly periods post treatment. Chemotherapy not recorded in
in-patient HES, but recorded in cancer registry data which was
measured in a time-independent manner, as treatments in the
cancer registry are recorded in as a binary variable, meaning that
the time of therapy could not be ascertained. Platelet count was
categorised into ‘low’ (o140 106 ml 1), ‘normal range’ (140–
400 106 ml 1) and ‘high’ (4400 106 ml 1).
A survival analysis was performed to determine the risk of death
following VTE. To eliminate the likelihood of immortal time bias
(whereby patients in the VTE group appear to survive for longer
due to them having survived long enough to be diagnosed with
VTE), we defined VTE as a time-varying covariate, where patients
started in the ‘No VTE’ group and were switched to the ‘VTE’
group at the date of VTE diagnosis. All data management and
statistical analysis were performed using Stata version 11
(Statacorp, College Station, TX, USA).
This study was approved by the Independent Scientific Advisory
Committee, protocol number- 10_091.
RESULTS
Patient characteristics. A total of 10 598 people were diagnosed
with lung cancer between 1997 and 2006 (Table 1). Median age at
cancer diagnosis was 72 years (IQR, 64–79 years). Among patients
whose cancer pathology was recorded (63.0%), small cell made up
19.4% of the population, while for non-small cell patients,
squamous cell was the most commonly occurring subtype
(37.9%), followed by adenocarcinoma (24.5%). Stage recording in
these databases only occurred in 29.7% of cases. Of these, almost
two-thirds (62.5%) were recorded as having metastatic disease.
Only 10.8% of the sample underwent surgery (29.9% local/
regional, 2.9% metastatic), while 24.9% underwent chemotherapy.
First surgery occurred on average 12 days (IQR, 0–54) after
the recorded cancer diagnosis; among patients who had both
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chemotherapy and surgery, the first record of chemotherapy was
an average of 69 days (IQR 24–387 days) after surgery.
Diagnosis of VTE was recorded in 364 cases among 9284
person-years of follow-up, corresponding to a rate of 39.2 per
1000 person-years (95% confidence Interval, CI, 35.4–43.5).
This rate was 11.8 times (95% CI, 10.6–13.1) higher than in age-
matched controls as shown in our previous paper from this cohort
(Walker et al, 2012). The median time to VTE diagnosis was 107
days (IQR 37–336 days). Full characteristics of patients can be
found in Table 1. Figure 1 describes when VTE occurred in this
population. Here, it is evident that the risk of VTE is mostly
clustered around the time of diagnosis, with risk slowly declining
subsequently. The risk of VTE in the first 6 months following
diagnosis was 76.7 per 1000 person-years (CI 67.5–87.2), declining
to 35.6 (CI 27.3–46.3) in the following 6 months, and 15.8
(CI 12.6–19.9) beyond 1 year from diagnosis.
Patient and tumour-related factors and risk of VTE. The best
non-treatment predictors of VTE were histology, cancer stage and
diagnosis route, while cancer grade, pre-existing comorbidity,
BMI, age and smoking were less strong predictors, or did not affect
VTE risk (Table 2).
The multivariable model revealed those with adenocarcinoma
had higher risk of VTE than squamous cell patients (hazard ratio
(HR)¼ 1.9, CI 1.4–2.6). Patients with distant metastases had a high
absolute rate of VTE (81.7, CI 65.0–102.8), but the effect size
of stage was reduced in the multivariable model. The variables
with the greatest confounding effect were surgery and chemother-
apy. However, distant metastases still double the risk compared
with local disease (HR¼ 1.8, CI 1.1–2.9). Patients with higher
tumour grade had a non-significantly elevated rate of VTE.
Body mass index had little effect on VTE, while there was a
trend towards lower risk in older patients (P¼ 0.016). Patients who
smoke had a higher absolute rate of VTE than those who did not
(univariate HR¼ 1.4, CI 1.1–1.7), but this effect was removed
after adjustment in the multivariable model (HR¼ 1.2, CI 0.9–1.5).
Both pre-existing comorbidity and platelet count had no significant
effect on VTE risk.
Treatment-related factors and risk of VTE. We assessed the
effect of different treatment routes on VTE risk, with route of
diagnosis and chemotherapy being the strongest predictors of risk.
Diagnosis route. Patients diagnosed via emergency hospitalisation
had substantially higher rates of VTE than those diagnosed
through elective hospitalisation. The rate of VTE for emergency
hospitalisation was 71.8 per 1000 person-years (CI 59.4–86.9) vs
33.8 (CI 29.6–38.4) for non-emergency admissions. This elevated
risk remained evident in the multivariable Cox model, with an HR
of 1.6 (CI 1.3–2.1).
Surgery. Despite some elevated rates in patients after surgery,
none of these reached statistical significance in comparison with
patients who did not have surgery. However, it is notable that VTE
rate in surgery patients fell substantially below that of non-surgical
patients after recovery from surgery (HR¼ 0.4, CI 0.2–0.5). This
may reflect the longer follow-up/survival time in this time category
(median follow-up 25 months vs 3 months for non-surgical
patients) where disease and treatment effects are likely to have less
influence.
Table 1. Characteristics of lung cancer patients with and
without VTE
No VTE % VTE %
Total 10 234 364
Histology
Small cell 1259 12.3 33 9.1
Squamous cell 2454 24.0 74 20.3
Adenocarcinoma 1532 15.0 100 27.5
Other 1177 11.5 43 11.8
Unknown 3812 37.2 114 31.3
Cancer stage
Local disease 745 7.3 29 8.0
Regional disease 394 3.8 19 5.2
Distant metastases 1902 18.6 73 20.1
Unknown 7193 70.3 243 66.8
Route of diagnosis
Elective hospitalisation 4944 48.3 227 62.4
Emergency (A&E) 1805 17.6 52 14.3
Emergency (other) 2024 19.8 54 14.8
No diagnostic
hospitalisation
1461 14.3 31 8.5
Age bands
o50 345 3.4 20 5.5
50–59 1291 12.6 74 20.3
60–69 2727 26.6 131 36.0
70–79 3838 37.5 113 31.0
X80 2033 19.9 26 7.1
Comorbidities
0 3625 35.4 136 37.4
1–3 5557 54.3 188 51.6
X4 1052 10.3 40 11.0
Smoking
No 7669 74.9 278 76.4
Yes 2565 25.1 86 23.6
BMI
Underweight 331 3.2 9 2.5
Ideal 2378 23.2 87 23.9
Overweight 1739 17.0 86 23.6
Obese 503 4.9 23 6.3
Morbidly obese 132 1.3 4 1.1
Missing 5151 50.3 155 42.6
Surgery
No 9155 89.5 295 81.0
Yes 1079 10.5 69 19.0
Chemotherapy
No 7644 74.7 202 55.5
Yes 2478 24.3 162 44.5
Radiotherapy
No 7096 69.3 226 62.1
Yes 3165 30.9 138 37.9
Abbreviations: BMI¼body mass index; VTE¼ venous thromboembolism.
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Figure 1. Histogram to describe the frequency of VTE occurrence over
the first 2 years after diagnosis (time 0 is the date of diagnosis).
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Chemotherapy. Chemotherapy patients exhibited the highest
absolute VTE rate within this analysis (103.2 per 1000-person
years during chemotherapy, CI 75.1, 141.8). If we investigate
chemotherapy as a binary variable, that is, ever or never had
chemotherapy, then the multivariable hazard ratio is 1.3 (CI 1.1–
1.7). Although VTE risk in the time before chemotherapy is similar
to that in non-chemotherapy patients (HR¼ 1.1, CI 0.7–1.6), the
risk doubled during chemotherapy (HR¼ 2.4, CI 1.6–3.5) and then
declined following cessation of chemotherapy, with a similar risk to
baseline 2 months after chemotherapy ended.
Radiotherapy. Radiotherapy as defined by cancer registry data did
not significantly affect the risk of VTE, though we were unable to
assess the time-varying effect of radiotherapy as per surgery and
chemotherapy due to low recording in the HES data.
Survival of lung cancer patients. The effect of VTE diagnosis on
survival was explored to determine its extent and whether any
observed changes were independent or due to differences in patient
mix. With VTE defined as a time-varying covariate, there is a clear
increase in risk of death for patients with VTE (Figure 2 and
Table 3) with an overall univariable HR of 1.7 (CI 1.5–1.8).
Adjustment for the variables described in Table 2 only changes the
HRs by a small amount (overall HR¼ 1.5, CI 1.4–1.6), while the
proportional hazards assumption was not broken (P¼ 0.143). We
found that there was a significant interaction between VTE and
both histology (P¼ 0.017) and diagnosis route (Po0.001) but not
between VTE and stage (P¼ 0.108). For histology, VTE appears to
have little effect on survival in small cell patients, but is similar to
the overall effect for other morphologies (Table 3). Additionally,
VTE diagnosis seems to affect survival less in patients diagnosed
through emergency admission. Additionally, PE and DVT were not
found to affect survival in significantly different ways (PE HR: 1.6,
CI 1.4–1.8; DVT 1.4, CI 1.2–1.5).
DISCUSSION
This study was able to determine the estimates of VTE risk for a
wide range of potential risk factors related to lung cancer.
Although the baseline rate of VTE remains higher in lung cancer
than for most other cancer sites (Walker et al, 2012), we identified
several groups of lung cancer patients with an exceptionally high
rate of VTE. Figure 1 demonstrates that VTE events tend to cluster
around the date of diagnosis and so we sought to determine the
risk factors associated with these VTE events. Patient groups with
the highest rates of VTE included those with adenocarcinoma,
metastatic disease, emergency hospital admission around diagnosis
and those receiving chemotherapy. From these data, it is apparent
that grade, surgery, radiotherapy, comorbidity, BMI, age, smoking
and platelet count are less important predictors of VTE in the lung
cancer population. We also found that patients diagnosed with
VTE had poorer survival on average.
It has been reported previously that adenocarcinoma patients
may be at higher risk of VTE than other histologic subtypes (Blom
et al, 2004; Tagalakis et al, 2007; Chew et al, 2008; Kadlec et al,
2014), indeed many other cancer sites with high incidence rates of
VTE, such as pancreatic and bladder cancers are adenocarcinomas
(Walker et al, 2012). Cancer stage is widely assumed to be a strong
risk factor for VTE and our study agrees with that assumption, it
does however show that much of the increased risk in people with
metastatic disease may be due to confounding by other factors,
with adjustment for surgery and chemotherapy accounting for the
most of the difference between univariable and multivariable
models. The increase in VTE rates in patients with emergency
hospital admission around diagnosis is complex and likely to be a
partial proxy indicator for late-stage disease, but also for
performance status. Our data were mainly from an era with less
emphasis on the use of thromboprophylaxis in medical in-patients,
and the now widespread use of thromboprophylaxis assessment on
admission may alter this finding.
The results we observed for platelet count in relation to VTE risk
conflict somewhat with previous results. Although our model shows
little effect, previous studies have demonstrated an association
between high platelet counts and VTE (Zecchina et al, 2007).
Although it is possible that there is no association with platelet count
in this population, there are potential alternative explanations. It is
likely that platelet count is confounded by other patient attributes, for
example, stage or chemotherapy treatment that are imperfectly
adjusted for, leading to residual confounding. Alternatively, patients
with missing platelet counts may not be missing at random, meaning
our results are liable to reflect the reasons that patients had their
platelet levels recorded in these data as much as they are any direct
effect raised platelet levels have on thrombosis risk. Age appeared to
have a trend in the opposite direction to the overall cancer
population (Walker et al, 2012), with lower rates in older age
groups. This may be due to either less aggressive treatment in these
higher age groups or alternatively reduced levels of investigation. This
inverse trend has also been observed in other populations, for
example in the California Cancer Registry (Chew et al, 2008) and
Florida Medicaid Study (Huang et al, 2012).
The Californian study is the previous study most comparable to
ours. They used a larger patient group, but reported on fewer
potential risk factors than our study. Of those that were common
to both studies, there was agreement in terms of the size and
direction of the observed effects for age, cancer stage, pathology
and surgery. They are, however, at odds in terms of comorbidity.
Chew et al observed increasing VTE risk with increased
comorbidity, whereas our study showed no such effect. This
finding is replicated by Connolly et al, who also found that a higher
comorbidity score was associated with greater VTE risk. Interest-
ingly however, when comorbidities were examined individually by
Connolly et al, only congestive heart failure was found to be
associated. The study by Connolly et al also presents some
interesting data on chemotherapy. It demonstrates that the
majority of VTE events in the chemotherapy population occur in
the first months after diagnosis, though does not distinguish
chemotherapy from the period post chemotherapy as in our study.
It is worth noting that in this and all similar studies, some of the
increase in risk observed in chemotherapy patients could be due to
ascertainment bias, that is, those receiving chemotherapy are more
likely to have a CT scan which could identify occult PE.
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Figure 2. Survival of lung cancer patients according to diagnosis of
VTE. To reduce the effect of immortal time bias, VTE was defined in a
time-varying manner, whereby patients start in the ‘no VTE’ group, and
are switched to the ‘VTE’ group after VTE diagnosis.
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Table 2. Rates of VTE in relation to potential risk factors
Absolute rates (per 1000 person-years) Univariate Cox model Multivariate Cox modela
Events Time Rate 95% CI HR 95% CI HR 95% CI
Histology
Small cell 33 1.0 31.7 22.5–44.5 1.2 0.8–1.9 0.7 0.4–1.0
Squamous cell 74 3.0 24.9 19.8–31.2 Reference Reference
Adenocarcinoma 100 1.9 51.4 42.3–62.6 2.1 1.5–2.8 1.9 1.4–2.6
Other 43 1.2 36.3 27.0–49.0 1.5 1.0–2.1 1.3 0.8–1.8
Unknown 114 2.1 53.4 44.5–64.2 2.1 1.5–2.8 1.8 1.3–2.4
Stage
Localised 29 1.4 20.9 14.5–30.1 Reference Reference
Regional 19 0.6 31.7 20.2–49.7 1.5 0.9–2.7 1.3 0.7–2.3
Distant Metastases 73 0.9 81.7 65.0–102.8 3.6 2.4–5.6 1.8 1.1–2.9
Unknown 243 6.4 38.0 33.5–43.1 1.8 1.2–2.6 1.3 0.8–1.9
Grade
Well differentiated 7 0.3 24.0 11.4–50.3 Reference Reference
Moderately well
differentiated
40 1.5 26.8 19.7–36.6 1.1 0.5–2.4 1.3 0.6–2.9
Poorly differentiated 91 2.1 43.3 35.2–53.1 1.7 0.8–3.7 1.6 0.7–3.4
Unknown 226 5.4 41.9 36.8–47.7 1.7 0.8–3.5 1.3 0.6–2.9
Route of diagnosis
Elective hospitalisation 227 6.7 33.8 29.6–38.4 Reference Reference
Emergency hospitalisation 106 1.5 71.8 59.4–86.9 2.0 1.6–2.6 1.6 1.3–2.1
No in-patient hospitalisation 31 1.1 28.7 20.2–40.8 0.8 0.6–1.2 0.7 0.5–1.0
Surgery
No surgery 295 5.8 50.7 45.2–56.8 Reference Reference
Before surgery 5 0.2 30.9 12.9–74.2 0.6 0.2–1.5 0.6 0.3–1.6
During surgery
hospitalisation
3 0.0 101.0 32.6–313.2 1.9 0.6–6.0 2.0 0.6–6.4
1 month after 4 0.1 45.7 17.1–121.7 0.9 0.4–2.5 1.0 0.4–2.7
2 months after 3 0.1 37.1 12.0–115.1 0.7 0.2–2.3 0.8 0.2–2.4
3 months after 6 0.1 78.0 35.1–173.7 1.5 0.7–3.4 1.5 0.7–3.4
Subsequent timeb 48 3.0 15.8 11.9–21.0 0.3 0.2–0.4 0.4 0.2–0.5
Chemotherapy
No chemotherapy 202 6.2 32.5 28.3–37.3 Reference Reference
Before chemotherapy 24 0.6 42.6 28.5–63.5 1.3 0.8–1.9 1.1 0.7–1.6
During chemotherapy 38 0.4 103.2 75.1–141.8 3.1 2.2–4.4 2.4 1.6–3.5
1 month after 10 0.1 86.8 46.7–161.2 2.6 1.4–4.9 2.0 1.0–3.8
2 months after 5 0.1 53.6 22.3–128.7 1.5 0.6–3.8 1.2 0.5–3.0
3 months after 0 0.1 0.0 — —
Subsequent timeb 30 1.0 28.7 20.1–41.1 0.8 0.6–1.2 0.7 0.5–1.1
Outpatient chemotherapyc 55 0.8 69.1 53.1–90.0 2.1 1.6–2.8 1.7 1.2–2.3
Radiotherapy
No 226 6.1 36.9 32.4–42.1 Reference Reference
Yes 138 3.2 43.7 37.0–51.6 1.1 0.9–1.4 0.9 0.7–1.1
Comorbidity
0 136 3.4 40.5 34.2–47.9 Reference Reference
1–3 188 4.9 38.1 33.1–44.0 1.0 0.8–1.2 1.0 0.8–1.3
43 40 1.0 40.3 29.5–54.9 1.1 0.8–1.5 1.1 0.7–1.6
BMI
Underweight 9 0.3 30.3 15.8–58.2 0.8 0.4–1.5 0.7 0.4–1.5
Ideal 87 2.3 37.8 30.6–46.6 Reference Reference
Overweight 86 1.9 45.0 36.4–55.6 1.2 0.9–1.6 1.4 1.0–1.8
Obese 23 0.5 44.2 29.4–66.5 1.2 0.8–1.9 1.2 0.8–2.0
Morbidly obese 4 0.2 24.9 9.3–66.2 0.7 0.2–1.8 0.7 0.2–1.9
Missing 155 4.1 37.9 32.4–44.4 0.9 0.7–1.2 1.0 0.8–1.3
Age
o50 20 0.6 35.7 23.1–55.4 Reference Reference
50–60 74 1.6 46.0 36.7–57.8 1.3 0.8–2.1 1.3 0.8–2.1
60–70 131 3.0 43.1 36.3–51.1 1.2 0.8–1.9 1.2 0.8–2.0
70–80 113 3.1 36.3 30.2–43.6 1.0 0.6–1.6 0.9 0.6–1.5
480 26 1.0 27.2 18.5–40.0 0.7 0.4–1.3 0.6 0.3–1.0
Smoking
No 278 7.6 36.6 32.6–41.2 Reference Reference
Yes 86 1.7 50.7 41.0–62.6 1.4 1.1–1.7 1.2 0.9–1.5
Platelet count
Low (o140) 14 0.2 59.4 35.2–100.3 1.6 0.9–2.8 1.5 0.9–2.6
Normal (140–400) 195 5.5 35.3 30.7–40.6 Reference Reference
High (4400) 50 1.4 36.8 27.9–48.5 1.0 0.7–1.4 0.9 0.6–1.2
No count 105 2.2 48.5 40.0–58.7 1.3 1.0–1.6 1.1 0.8–1.4
Abbreviations: BMI¼body mass index; CI¼ confidence interval; VTE¼ venous thromboembolism.
aHazard ratios adjusted for all other variables in table.
bSubsequent time refers to the time after the procedure until the completion of follow-up.
cOutpatient chemotherapy refers to those patients who were recorded as having chemotherapy in the cancer registry, but did not have a record of this in the in-patient hospital records.
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Chemotherapy is increasingly considered as a powerful risk
factor for VTE in the cancer population, to the extent that a well-
validated risk prediction tool has been developed specifically for
the population receiving chemotherapy (Khorana et al, 2008).
Although this model takes cancer site into account, it is assumed
that risk factors within the model exert a similar effect on VTE risk
regardless of the cancer site. The pattern of VTE predictors in this
study differs substantially from previous work carried out in the
same data for colorectal cancer (Walker et al, 2014), where notably
age and surgery were much stronger predictors of VTE. Risk
factors also differ in breast cancer in these data, where age and BMI
are strong predictors, with chemotherapy by far the greatest risk
factor (Walker et al, 2016). This highlights the possible benefit of
developing individual risk scores for each cancer type.
Although we found that patients with a VTE diagnosis had
overall poorer survival than those without, it is difficult to infer
causality to this finding. It is possible that some of the deaths are
directly attributable to VTE, though given that the additional risk
of death remains throughout follow-up for patients with VTE it is
also likely to be due to patient mix and residual confounding (e.g.,
those with a VTE are more likely to die due to generally more
advanced disease). We also determined that the effect of VTE on
survival was less in patients with small cell lung cancer and those
diagnosed through emergency admission. This may be due to these
patients having a higher baseline hazard of death, making the
additional hazard added by VTE diagnosis is less important.
An important strength of this study is that we used routinely
recorded data which, in contrast to many previous studies which,
for example use only hospitalised patients, only chemotherapy
patients (Khorana et al, 2008) or only non-small cell patients
(Tagalakis et al, 2007), should contain a representative sample of
the whole lung cancer population. Unlike previous research, we
assessed both surgery and chemotherapy in a time-dependent
manner so that rates of VTE can be compared before, during and
after therapy within the same group of patients.
Study limitations include missing data, on cancer stage
especially, which undoubtedly reduced the power of our study in
examining some risk factors, as well as the ability to adjust for
confounding. Additionally, the level of missing data for stage
particularly made it difficult to use imputation to analyse the data.
Although our overall sample size was large, smaller patient
subgroups presented limited ability to determine the detailed
effects of risk factors, such as those undergoing surgery. It is
possible that risk factors such as BMI would have shown more
consistent trends if the highest and lowest categories had not been
limited by small patient and event numbers. Another limitation is
that radiotherapy recording within our database was limited to a
single binary indicator variable. The implications of this are that we
may have under-reported the level of radiotherapy within the
population, and that we could not investigate time-varying effects
of radiotherapy. Similarly, for patients who received outpatient
chemotherapy while we were able to identify them as a separate
risk group, we could not assess how their risk changed in relation
to specific time intervals following chemotherapy.
We were unable to measure the effect of performance status on
the risk of VTE, which is considered as an important risk factor for
VTE as immobility; however, we did include a number of variables,
such as route of diagnosis, stage and comorbidity, which are likely
partial proxy indicators for performance status. Conversely, it is
not known in this study whether route of diagnosis is a risk factor
in its own right, or merely a proxy indicator for disease stage and
performance status. It is also possible that a part of the obtained
results are due to the measured risk factors being a marker for
increased imaging, which we were not able to measure. For
example, patients undergoing chemotherapy are arguably more
likely to undergo staging CT scans, which might detect VTE events
that are not clinically significant.
The clinical benefits of knowing which patients are most at risk
of VTE and when this risk is highest may arise from knowing when
to give thromboprophylaxis. Our stratification of VTE risk allows
targeting of patients with exceptionally high risk, potentially
preventing cases of VTE, which is in itself desirable given the
potential reduction in morbidity. Conversely, there are groups of
patients who are at a low risk of VTE, where thromboprophylaxis
would cause a net harm due to side effects including bleeding and
the inconvenience of a daily heparin injection. Although
determination of the threshold above which the benefits of
prophylaxis may outweigh the harms is beyond the scope of the
present work, the absolute risks presented here are likely to help in
the planning of future prophylaxis clinical trials where patients are
selected for inclusion on the basis of their underlying risk.
Our study demonstrates that despite adjusting for multiple
variables, patients who have a VTE event have a reduced survival
in comparison with those who do not. This could be explained
partially by increased deaths directly attributable to VTE, but could
also be due to residual confounding (e.g., by disease severity).
Though the recent trials testing the use of thromboprophylaxis in
cancer patients have observed little corresponding survival benefit,
they have been carried out in relatively large, roughly aggregated
groups of patients, such as metastatic cancer patients (Verso et al,
2010) or chemotherapy patients (Agnelli et al, 2012). It is therefore
possible that the improved targeting of thromboprophylaxis
facilitated by this and similar studies will allow the potential
survival benefits of preventing VTE events to be realised.
We have highlighted that despite risk of VTE being high in the
whole lung cancer population, there are groups of patients where
particular attention must be paid, namely those with metastatic
disease and those undergoing chemotherapy. There are also groups
that have much lower risk, such as long-term survivors not
receiving treatment. It is imperative that future randomised trials
use these and similar data when selecting patients for
thromboprophylaxis.
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